(주)셀렉스라이프사이언스

News

ILIAS is the Leader of Next-Generation Exosome Therapeutics.

[ENG] 보도자료

ILIAS Biologics Expands Leadership Team with the appointment of Taejin Ham as Chief Operating Officer & Jun Park as Chief Scientific Officer

페이지 정보

  • 작성자 : ILIAS Biologics
  • 작성일 : 20-01-29 18:46
  • 조회 : 724회

본문


29 Jan 2020


ILIAS Biologics Expands Leadership Team with the appointment of Taejin Ham as Chief Operating Officer & Jun Park as Chief Scientific Officer

 

a246b6a9715fd5042288eb8b7a9600f0_1594173971_7546.JPG
 

Former CEO of Celgene Korea, Taejin Ham joins ILIAS Biologics as Executive Vice President, Chief Operating Officer. Prior to Celgene, he worked for Eli Lilly and Company in multiple leadership roles. Former US FDA Reviewer, Jun Park also joins ILIAS Biologics as Executive Vice President, Chief Scientific Officer. He served as an FDA reviewer for over 11 years in charge of evaluating the product quality and manufacturing process for biopharmaceutical products. With the addition of two executives, ILIAS is expecting to see the acceleration of the next stage of growth. 

 

Press Link (Korean): http://www.yakup.com/news/index.html?mode=view&cat=12&nid=239989

개인정보취급방침

닫기

이메일주소무단수집거부

닫기

사이트맵

사이트맵

몬트리올의정서
국내이행법령
사업안내
특정물질 수출입
알림·자료실
민원서비스
닫기